89.57 0.00 (0.00%)
After hours: 4:53PM EST
|Bid||89.55 x 1100|
|Ask||89.64 x 1400|
|Day's range||88.91 - 89.96|
|52-week range||70.89 - 89.96|
|Beta (5Y Monthly)||0.53|
|PE ratio (TTM)||25.03|
|Earnings date||5 Feb 2020|
|Forward dividend & yield||2.44 (2.74%)|
|1y target est||97.56|
Lilly (LLY) initiates a phase III study on its oral RET inhibitor, selpercatinib, in treatment-naive, RET fusion-positive NSCLC patients.
Investing.com – Stocks pushed higher Thursday afternoon on reports the United States and China have mostly agreed on a phase one trade deal.
AstraZeneca's (AZN) Imfinzi becomes the first immunotherapy to receive approval in China for treating unresectable, stage III NSCLC, which has not progressed following chemotherapy and radiation therapy.
Data from Exploratory Analysis Show KEYTRUDA Improved Overall Survival as Monotherapy for the First-Line Treatment of NSCLC Regardless of KRAS
Sanofi (SNY) intends to amend its antibody collaboration with Regeneron related to Kevzara and Praulent into a royalty-based agreement. Agreement terms for Dupixent to remain intact.
The FDA accepts Roche's (RHHBY) allergic asthma drug Xolair's sBLA for the treatment of nasal polyps in adult patients aged 18 years or above with inadequate response to intranasal corticosteroids.
Merck (MRK) offers to acquire ArQule for a deal value of $2.7 billion. The transaction will add ArQule's lead investigational candidate ARQ 531 to Merck's oncology portfolio.
The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.
AstraZeneca's (AZN) Lynparza receives approval in China for first-line maintenance treatment of advanced ovarian cancer with BRCA-mutation.
The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.
The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo. Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.
Bristol-Myers (BMY) and Acceleron Pharma Inc.'s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDA's Oncologic Drugs Advisory Committee.
Roche (RHHBY) obtains FDA approval for Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic NSCLC.